

# **Open Targets Platform Analysis and visualisation for early drug discovery**



## **Coursebook**

**European Molecular Biology Laboratory  
European Bioinformatics Institute  
8<sup>th</sup> March 2017**

**Denise Carvalho-Silva  
Open Targets Outreach**

## Notes

This course is based on the December 2016 release of our Open Targets Platform.

Some useful links:

1) About the Open Targets Consortium

[www.opentargets.org/about](http://www.opentargets.org/about)

2) About the Open Targets Platform

[www.targetvalidation.org/about](http://www.targetvalidation.org/about)

3) Our publication

[www.bit.ly/OpenTargets](http://www.bit.ly/OpenTargets)

4) Details on the latest Platform release

<https://blog.opentargets.org/open-targets-platform-our-new-release-is-out-2/>

Feel free to tackle questions relative to your own research instead of following the ones provided in this course booklet.

Questions or Feedback?

[support@targetvalidation.org](mailto:support@targetvalidation.org)

## **TABLE OF CONTENTS**

<b>OVERVIEW.....</b>	<b>4</b>
<b>INTRODUCTION TO OPEN TARGETS.....</b>	<b>5</b>
<b>OPEN TARGETS PLATFORM: LIVE DEMOS.....</b>	<b>8</b>
Demo 1 .....	9
Demo 2.....	16
Demo 3.....	24
<b>HANDS-ON EXERCISES.....</b>	<b>29</b>
Exercise 1.....	29
<b>EXTRA HANDS-ON EXERCISES .....</b>	<b>30</b>
Exercise 2.....	30
Exercise 3.....	30
<b>QUICK GUIDE TO DATABASES .....</b>	<b>32</b>

## **OVERVIEW**

Open Targets is a public-private initiative to generate evidence on the validity of therapeutic targets based on genome-scale experiments and analysis. We are working to create an R&D framework that applies to a wide range of human diseases, and we want to share this data openly with the scientific community.

The consortium was launched in March 2014 under the name of Centre for Therapeutic Open Targets (CTTV) and started with GlaxoSmithKline (<http://www.gsk.com/>), the Wellcome Trust Sanger Institute (<http://www.sanger.ac.uk/>) and the European Bioinformatics Institute (<http://www.ebi.ac.uk/>). In February 2016, a fourth institution namely Biogen (<https://www.biogen.com/>) joined the initiative and the consortium was rebranded to Open Targets in April 2016.

In the process of drug discovery, the *validation* of a target refers to the creation of a specific entity that modulates that target's activity to provide therapeutic benefit to individuals with a disease. The ultimate validation of a target is the creation of an effective therapeutic molecule. This is a long and costly endeavour with more failures than successes. The goal of Open Targets is to transform this process by predicting if the modulation of a target is likely to provide therapeutic benefit. This would be done much earlier in the drug discovery process than is currently possible and far in advance of having a final, approved medicine.

Points covered in this workshop:

- The projects of Open Targets consortium
- An introduction to the Open Targets Platform
- Browsing the Platform
- Pointing to alternative ways to access the data

## **INTRODUCTION TO OPEN TARGETS**

Open Targets employs large-scale human genetics and genomics data to change the way drug targets are identified and validated. We have established a set of projects to develop both the data and analytical processes that implicate targets as valid, and the core platform to provide the information to a diverse audience of users.

The core bioinformatics team develops pipelines and a database to integrate existing target data. The core also designed, created and maintains the Open Targets Platform, a public web portal to serve the integrated data and views.

Our experimental projects focus on providing insights in the identification of targets relevant to key therapeutic areas namely:

- Oncology
- Inflammatory bowel diseases (IBD)
- Respiratory disease
- Inflammation and immunity
- Neurodegenerative diseases

We also aim to develop standard epigenome profiles of cell models in use within the pharmaceutical industry and academia and establish a systematic approach for the determination of human biological and disease relevance.

More details can be found in our [Projects](#) page.

### **Retrieving data from Open Targets with our Platform**

The Open Targets Platform is a web application that integrates and displays publicly available biological data to foster the discovery and prioritisation of targets for new therapies. We use data sources as diverse as Gene2Phenotype, IntOGen, GWAS, UniProt, ChEMBL, Expression Atlas, Cancer Census, Reactome and EuropePMC as pieces of evidence to support target-disease associations. The associations are scored using objective statistical and computational techniques.

In our release (December 2016), the Platform provides information on 31,071 targets; 8,659 diseases; 4.9 million evidence; and 2.5 million target-disease associations.

In addition to the web application, we include the data dumps, a REST API and a Python client.

The Open Targets Platform is aimed at users from both academia and industry, whether they want to browse a target on a gene by gene (or disease by disease) basis, carry out more complex queries using the API, or download all evidence and association objects for downstream analyses.

### **Synopsis: what can I do with the Open Targets Platform?**

- Find out which targets are associated with a disease
- Explore the evidence supporting this target-disease association
- Export a table with the FDA drugs currently in clinical trials
- Discover if there other diseases associated with a given target
- Get the association of a target with diseases from different therapeutic areas
- Find target specific information, such as baseline expression, protein structure, alternatively spliced transcripts, gene trees
- Get disease target specific information, such as a classification based on the ontology of the disease and the drugs mapped to it

## **Documentation and support**

[Data sources](#) in the Open Targets Platform

View our [FAQs](#)

[Email us](#)

## **Connect with us**

[Open Targets Blog](#)

Follow us on [Twitter](#)

Check our page on [Facebook](#) and [LinkedIn](#)

## **Further reading**

Koscielny, G. *et al.* Nucleic Acids Res (2017 Database Issue):  
<http://nar.oxfordjournals.org/content/early/2016/11/29/nar.gkw1055>

A breakthrough article from Nucleic Acids Research:  
<http://www.narbreakthrough.com/>

## **OPEN TARGETS PLATFORM: LIVE DEMOS**

We will guide you through the website using renal cell carcinoma, (papillary) as an example and exploring the *MET* gene based on 'Reconstruction of a Functional Human Gene Network, with an Application for Prioritizing Positional Candidate Genes' by Franke et al. AJHG 2006).


The following points will be addressed during the walkthrough:

- How to find targets associated with renal cell carcinoma
- How to filter down the number of targets based on specific evidence
- How to find the data sources used to support the target-disease association
- How to look for other diseases (than renal cell carcinoma) associated with a given target
- How to visualise a target in a browser-like view
- How to find out how strong the association between a target and a disease is
- How to find drugs currently in clinical trials
- How to filter **our** associations by **your** list of target genes




## Demo 1

Go to [www.targetvalidation.org](https://www.targetvalidation.org) and search for one of the diseases described in the paper (renal cell carcinoma).



Select the first (best) hit:



You will see a page like this:

**Total number of targets associated with renal cell carcinoma**

4543 targets associated with renal cell carcinoma

**Data types (Genetic Associations, Drugs, etc)**

**Filter the results**

Filter by

1 to 50 of 4,543 targets

Target symbol	Association score	Genetic associations	Somatic mutations	Drugs	Affected pathways	RNA expression	Text mining	Animal models	Target name
MET									MET proto-oncogene, rec...
VHL									von Hippel-Lindau tumor ...
PBRM1									polybromo 1
PDGFRA									platelet derived growth fa...
RET									ret proto-oncogene
PDGFRB									platelet derived growth fa...
FGFR3									fibroblast growth factor re...
BRAF									B-Raf proto-oncogene, s...
FLT4									fms related tyrosine kinas...

The current release of the Open Targets Platform (December 2016) lists 4543 targets associated with renal cell carcinoma.

The data types supporting these results are based on Genetic association, Somatic mutations, Drugs, RNA expression, Text mining, and Animal models.

**Note:** We will go through these data types (and the data sources that make the data types) later in this tutorial.

Check our help page to find out more about our data sources: [https://targetvalidation.org/data\\_sources](https://targetvalidation.org/data_sources).

You can filter the number of associations by 'Data types', 'Pathway types', 'Target class' and by uploading 'Your target list':

#### A) Data types

- Genetic associations (e.g. GWAS catalog)
- Somatic mutations (e.g. Cancer Gene Census, EVA)
- Drugs (from ChEMBL)
- Affected Pathways (from Reactome)
- RNA expression (from Expression Atlas)
- Text mining (from EuropePMC)
- Animal models (from PhenoDigm)

B) Pathway types

Signal Transduction

Metabolism

...

C) Target class

Enzyme

Membrane receptor

...

D) Your target list

Upload your own list of genes (in official gene symbols or Ensembl Gene IDs)

What are **Data types**, **Pathway types** and **Target class**?


We collect data from various sources and combine them into categories called Data types. Example of data sources are GWAS catalog and UniProt, both combined into Data types. Note that data from an individual source can contribute to different Data types, e.g. data from EVA is observed in two data types, Genetic associations and Somatic mutations.

'Pathway types' are defined by Reactome:


(<http://www.reactome.org/>),

whereas the categories within 'Target class' are defined by ChEMBL (<https://www.ebi.ac.uk/chembl/>).

Let's now filter the data to focus on 'Genetic associations' (Data type) only. The number of targets goes down to 15:

Open Targets Platform Survey About ▾ Help ▾ API ▾ Downloads Blog 

## 15 targets associated with renal cell carcinoma

 [View disease profile](#)

**Filter by** Showing 1 to 15 of 15 targets Search:

**Data types** Clear all ✕ Select all ✓

- ☒ Genetic associations (15)
  - ☐ GWAS catalog (8)
  - ☐ UniProt literature (5)
  - ☐ European Variation ... (4)
  - ☐ UniProt (3)
- ☐ Somatic mutations (526)
- ☐ Drugs (94)
- ☐ Affected pathways (0)
- ☐ RNA expression (3k)
- ☐ Text mining (2k)
- ☐ Animal models (1)

**Pathway types**

**Top targets with the overall score of 1**

Target symbol	Association score	Genetic associations	Somatic mutations	Drugs
PBRM1	1	1	0	0
HNF1A	1	1	0	0
SETD2	1	1	0	0
FLCN	1	1	0	0
EPAS1	1	1	0	0
MYC	1	1	0	0
HNF1B	1	1	0	0

Blank cells have no data to support the - association (score of 0)

These are targets associated with renal cell carcinoma based on genetic variants only. Genetic variants are SNPs (or short indels, or mutations) from the GWAS catalog, UniProt and EVA (European Variation Archive) sources only.

The table is sorted by default with the best hit on the top of the table i.e. *MET*. The best hit is the target that contains the highest overall association score. Different weight is given to different data types when computing the score:

Genetic association = Somatic mutations = drugs = pathways > RNA expression > Animal models > Text mining (lowest weight of all data types).

You can sort the table by alphabetical order of the list of targets, or by the association score (either overall or per data type e.g. Genetic

associations, Drugs, Text mining, etc). The association score varies from 0 to 1, the closer to 1 the stronger the association. This score is computed for each piece of evidence that is used to support the association. Individual scores within data sources and data types combined to give the overall score ('Association score' column in the table below):

Target symbol	Association score	Genetic associations	Somatic mutations	Drugs	Affected pathways	RNA expression	Text mining	Animal models	Target name
MET									MET proto-oncogene, rec...
VHL									
PBRM1									


Click here to sort the results by alphabetical order of the gene symbols

Click on the arrows to sort the results by score values of individual data types e.g. Animal models.

**Note:** More details on the scoring will be given towards the end of this tutorial.

To see which drugs are in clinical trials of this disease, we need to click on the 'View disease profile':

15 targets associated with renal cell carcinoma


[View disease profile](#)

Let's now expand the tab 'Drugs' to get a list of all drugs (n = 35 unique drugs in the December release) in different phases of clinical trials used in patients suffering from renal cell carcinoma. You can filter (and sort) the table by disease, phase of clinical trial (e.g. IV, the advanced phase), class of the target (e.g. isomerase), etc. You can also download this table in csv (comma separated value):

Drugs

Source: ChEMBL

Found 35 unique drugs:

EVEROLIMUS

Famitinib

GIRENTUXIMAB

INTERFERON ALFA-2A

IXABEPILONE

LINFANIB

MK-2206

NINTEDANIB

NIVOLUMAB

PANOBINOSTAT

PAZOPANIB

ROMIDEPSON

SEMAXANIB

SORAFENIB

SUNITINIB

Sunitinib

TANDUTINIB

TEMSIROLIMUS

TIVANTINIB

TIVOZANIB

VANDETANIB

VOLOCIXIMAB

VORINOSTAT

ZOLEDRONIC ACID

ALDESLEUKIN

APITOLISIB

AXITINIB

AZD-2014

Anlotinib

BEVACIZUMAB

CABOZANTINIB


CEDIRANIB

DOVITINIB

ERLOTINIB


Showing 1 to 10 of 1,000 entries

Search:




Drug Information							Gene-Drug Evidence	
Disease	Drug	Phase	Status	Type	Mechanism of action	Activity	Target class	Evidence source
renal cell carcinoma	<a href="#">EVEROLIMUS</a>	Phase IV	Recruiting	Small molecule	FK506-binding protein 1A inhibitor <a href="#">DailyMed</a>	antagonist	Isomerase	Curated from Clinical Trials Information <a href="#">↗</a>
renal cell carcinoma	<a href="#">EVEROLIMUS</a>	Phase IV	Completed	Small molecule	FK506-binding protein 1A inhibitor <a href="#">DailyMed</a>	antagonist	Isomerase	Curated from Clinical Trials Information <a href="#">↗</a>
renal cell carcinoma	<a href="#">EVEROLIMUS</a>	Phase IV	Recruiting	Small molecule	FK506-binding protein 1A inhibitor <a href="#">DailyMed</a>	antagonist	Isomerase	Curated from Clinical Trials Information <a href="#">↗</a>
clear cell renal carcinoma	<a href="#">AXITINIB</a>	Phase IV	Recruiting	Small molecule	Vascular endothelial growth factor receptor inhibitor <a href="#">DailyMed</a>	antagonist	Tyrosine protein kinase VEGFR family	Curated from Clinical Trials Information <a href="#">↗</a>

Scroll down to view the disease ontology (disease relationship) in the 'Classification' tab:



Renal cell carcinoma is the disease of interest in this tutorial, and is represented in green. Red nodes correspond to parental terms in relation to renal cell carcinoma, whereas its children terms (e.g. papillary renal cell carcinoma) are shown in blue. Click on any of disease names to get the targets associated with them:



The screenshot shows a hierarchical tree of diseases. A pop-up window for 'papillary renal cell carcinoma' is displayed, showing its EFO code and a list of associated genes. The pop-up window has a close button (X) in the top right corner.


papillary renal cell carcinoma	
EFO code	EFO_0000640
387 genes associated (Showing the first 10)	
MET	<a href="#">See Evidence</a>
NF2	<a href="#">See Evidence</a>
VHL	<a href="#">See Evidence</a>
SETD2	<a href="#">See Evidence</a>
PBRM1	<a href="#">See Evidence</a>

By using the EFO parent-child (subclass of) relationships, we derive new associations that may not have direct evidence. For instance, IBD is an autoimmune disease and the direct evidence of targets associated to IBD are propagated to the higher autoimmune level to allow users to find common targets across groups of related diseases (e.g. Ulcerative Colitis, Crohn's disease and IBD). In EFO, 'asthma' is a 'respiratory system disease' and 'childhood onset asthma' is a subclass of 'asthma'. Both evidence from 'asthma' and 'childhood onset asthma' are propagated to 'respiratory system disease'

## Demo 2

Let's now explore the evidence used to associate *MET* and papillary renal cell carcinoma.

Click on 'See Evidence' link at the end of the Demo 1 to land on a page like this:



The data types that support this association are (check the flower and the coloured petals):

Genetic association  
Drugs  
Animal models

**Note:** If you wish to suggest data types or resources we could/should incorporate in our Platform, please email them to:

support@targetvalidation.org.

The genetic evidence that supports the *MET*-papillary renal cell carcinoma comes from UniProt. Most variants are known in public databases such as dbSNP (note the rsID):



Genetic associations				
<div>Table <b>Browser</b></div>				
Rare diseases				
Source: UniProt, European Variation Archive (EVA), UniProt literature, Gene2Phenotype				
Showing 1 to 10 of 12 entries				
Search: <input type="text"/>				
Disease	Mutation	Gene-Disease Evidence	Evidence source	Publications
papillary renal cell carcinoma	N/A	Curated evidence	<a href="#">Further details in UniProt database</a>	5 publications
papillary renal cell carcinoma	<a href="#">rs121913673</a>	missense variant	<a href="#">Further details in UniProt database</a>	1 publication
papillary renal cell carcinoma	<a href="#">rs121913670</a>	missense variant	<a href="#">Further details in UniProt database</a>	1 publication
papillary renal cell carcinoma	<a href="#">rs121913244</a>	missense variant	<a href="#">Further details in UniProt database</a>	1 publication

In addition to the table above, you can also explore the ‘Genetic associations’ data in a Browser view.

In the Browser, you can zoom in and out, scroll along the genome and find out more about the gene (s), transcript (s), and the genetic variants (represented as lollipops) in the genomic region depicted.

We also provide links to Ensembl.

Genetic associations

Table **Browser**

Human Chr: 7

human 7:116647190-116823585

116,660,000 116,680,000 116,700,000 116,720,000 116,740,000 116,760,000 116,820,000

Mutations in common diseases

Mutations in rare diseases

sequence

Genes / Transcripts

MET-005> MET-003> MET-004> MET-002> MET-001> MET-201> MET-007>

Gene legend: ■ protein coding ■ processed transcript

**Variants legend:**

- Mutation in MET associated with papillary renal cell carcinoma
- Mutation associated with papillary renal cell carcinoma in other genes
- Variant in MET
- Other Variant

Click on the lollipop for more details on the variants

rs121913673

Ancestral allele C  
Allele string C/G  
Most severe consequence missense\_variant  
Location [Jump to sequence](#)  
target MET  
Associations  
papillary renal cell carcinoma 1 article  
Familial papillary renal cell carcinoma 1 article

To find out if there are drugs currently in clinical trials in patients with papillary renal cell carcinoma, let’s expand the ‘Drugs’ tab. There is just one drug (i.e. TIVANTINIB) on phase II of clinical trials.


Let’s now find out the mouse model with phenotypes that mimic the human disease. Still on the same page, scroll down to view the ‘Animal models’ tab. Click on it to see there is one mouse model mutated at

this gene, which has the following phenotypes: increased sarcoma incidence, glomerulonephritis and hydronephrosis:

Animal models				
Source: <a href="#">Phenodigm</a>				
Showing 1 to 1 of 1 entries				
Search: <input type="text"/>				
Disease	Phenotype - Phenotype Evidence		Model - Disease Evidence	Source
	Human	Mouse	Mouse model	
papillary renal cell carcinoma	<ul style="list-style-type: none"> <li>Papillary renal cell carcinoma</li> </ul>	<ul style="list-style-type: none"> <li>increased sarcoma incidence</li> <li>glomerulonephritis</li> <li>hydronephrosis</li> </ul>	<a href="#">Met<sup>tm40ny</sup>/Met<sup>+</sup></a> Involves: 129 * C57BL/6J	Phenodigm
Show <input type="text" value="10"/> entries <span>Previous</span> <span>1</span> <span>Next</span>				

We can now scroll back to the top of the page and click on the ‘MET’ link (next to the flower) to explore this target in more details, such as to find out its RNA expression levels across several tissues:

### Evidence for MET in papillary renal cell carcinoma



#### MET

MET proto-oncogene, receptor tyrosine kinase  
 Synonyms: HGFR, RCCP2, DFNB97

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including pr...

You will land on a page like this:

[Open Targets Platform](#)
[Survey](#)
[About](#)
[Help](#)
[API](#)
[Downloads](#)
[Blog](#)

# MET

MET proto-oncogene, receptor tyrosine kinase | [View associated diseases](#)

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor (HGF) and its related peptides. Ligand binding at the cell surface induces autophosphorylation and provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase/AKT pathway. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adult, MET is involved in the regulation of cell proliferation, differentiation and survival.

Synonyms: [HGFR](#) [RCCP2](#) [DFNB97](#) [Scatter factor receptor](#) [2.7.10.1](#) [HGF receptor](#) [Hepatocyte growth factor receptor](#) [SF receptor](#) [hepatocyte growth factor receptor](#) [Proto-oncogene c-Met](#)

Protein Information (from UniProt)

Variants, isoforms and genomic context

Protein baseline expression

RNA baseline expression

Gene Ontology

Protein Structure

Pathways

Drugs

Gene tree

Bibliography

Expand the ‘RNA baseline expression’ to find out in which tissues *MET* is highly expressed.


You will find two tabs in there: one with Expression Atlas data (including several projects), and one with GTEx data only:

RNA baseline expression

Expression Atlas

GTEx variability

Let’s have a look at the variability of expression data (in RPKM, Reads Per Kilobase Million, normalised for sequencing depth and gene length) from the GTEx project:



According to the GTEx plot available in the Open Targets Platform, kidney (cortex) is the tissue with the highest expression level for the *MET* gene. The variability of the mRNA expression is shown and includes the median RPKM value.

Let's now click on 'View associated diseases' to find out all diseases associated with the *MET* (apart from papillary renal cell carcinoma):

Open Targets Platform   Survey   About ▾   Help ▾

**MET**  
MET proto-oncogene, receptor tyrosine kinase

View associated diseases

You will land on a page like this:



in white (score of zero). You can show the 10 first entries and get the pagination for the remaining entries.

**This table can be exported in csv format** (look for the download button).

BubblesTableTree

Showing 1 to 50 of 169 entries


Search:

	Disease	Association score	Genetic associations	Somatic mutations	Drugs	Affected pathways	RNA expression	Text mining	Animal models	Therapeutic area
	neoplasm	1.00	1.00	0	1.00	1.00	0.23	0.10	0.30	
	cancer	1.00	1.00	0	1.00	1.00	0.23	0.09	0.29	neoplasm
	carcinoma	1.00	1.00	0	1.00		0.23	0.08	0.26	neoplasm
	renal carcinoma	1.00	1.00	0	0.78			0.06	0.09	neoplasm, kidney disease


*Tip: We colour code the cells in the table in different shade of blue as a visual way to convey the strength of the association (strongest association is coloured in dark blue). The score varies from 0 to 1. Hover over the cells in the table to view the numbers. Alternatively, you can select the cells in the table so that you can view the numerical values.*

- Tree view

In the Tree view, you can visualise the evidence across the therapeutic areas in a tree format that represents the relationships of diseases. Therapeutic areas have a square symbol (e.g. Genetic disorders), while the diseases (e.g. ovarian carcinoma) are represented as circles. The squares and circles are colour coded in blue, and the darker the blue, the stronger the association:



Regardless the view you choose to explore, you can filter the data to find out if there are other “Kidney diseases” associated with this target. There are five of them (including papillary renal cell carcinoma). The scores vary from 0.03 to 1.0.



### Demo 3

Filter the target association table for Alzheimer's based on a list of known targets.


Franke et al (2006) listed a several genes associated with Alzheimer's based on a functional gene network:

ENSG00000091513  
ENSG00000175899  
ENSG00000143801  
ENSG00000142192  
ENSG00000130203  
ENSG00000010704  
ENSG00000080815

Let's see which information is available in the Open Targets Platform that could help you to choose and prioritise a target for follow up. We can input this data as a list (in .txt) to filter the associations in Open Targets.

a) Which of those seven genes have the strongest association w/ Alzheimer's?

Firstly, let's search for Alzheimer's and then upload our target list onto the Platform:




The screenshot shows the Open Targets Platform interface. At the top, there is a navigation bar with links to Survey, About, Help, API, Downloads, and Blog. Below the navigation bar, the main heading reads "2586 targets associated with Alzheimers disease". A sidebar on the left contains a "Filter by" section with expandable categories: Data types, Pathway types, Target class, and Your target list. The "Your target list" section includes a "Choose File" button and the text "No file chosen". A red arrow points to this section. The main content area displays "Showing 1 to 50 of 2,586 targets" and a search bar. Below the search bar, a table of target associations is visible, with columns for Target symbol, Association score, Genetic associations, Somatic mutations, and Drugs. The table lists several targets: APP, PSEN1, SORL1, PSEN2, and ABCA7.

Target symbol	Association score	Genetic associations	Somatic mutations	Drugs
APP				
PSEN1				
SORL1				
PSEN2				
ABCA7				



Now, we can upload a text file containing our list of genes (either as official gene symbols from HGNC e.g. *SOX3*, or Ensembl gene IDs e.g. ENSG00000134595). The filter 'Your target list' is at the left hand side of the association page (you will need to scroll down to see this option):




The screenshot shows the Open Targets Platform interface. On the left, under 'Filter by', the 'Your target list' filter is expanded, showing an upload button and a list of target names found in a file. A red arrow points to this section. The main area displays a heatmap for 7 targets associated with Alzheimer's disease. The columns represent different data types: Target symbol, Association score, Genetic associations, Somatic mutations, Drugs, Affected pathways, RNA expression, Text mining, Animal models, and Target name. The rows list the targets: APP, PSEN1, PSEN2, APOE, TF, A2M, and HFE. The heatmap shows various association scores and data points for each target across the different categories. A legend at the bottom indicates the color scale for the heatmap, ranging from 0 (light blue) to 1 (dark blue).

The list should be uploaded and the resulting table will show the results of our analyses for that list of seven genes. This can help you prioritise which targets to follow up.

b) Are there any targets, which are membrane receptors?

We can now use the filter 'Target class' to focus on membrane receptors only. There is only one, APP (ENSG00000142192)

1 target associated with Alzheimers disease

 [View disease profile](#)

**Filter by**

**Data types** ▶

**Pathway types** ▶

**Target class** ▼

Clear all ✕ Select all ✓

☐ Ion channel (2) ▶

☐ Secreted protein (1)

☒ Membrane receptor (1)

**Your target list** ▼

Clear targets from Alzheimers\_list\_targets.txt ✕

Target names found in file (7) ▶

Have associations with Alzheimer... (1)

No associations found for Alzheim... (6)

Showing 1 to 1 of 1 targets

Search:

Target symbol Association score Genetic association


APP

Show 50 entries

No data


0 1

Score




c) Which amino acids of this membrane receptor correspond to the extracellular domain?

To explore more about the target itself, we can click on any cell of the resulting table then click on the target name, next to the flower:


 Open Targets Platform Survey

Evidence for APP in Alzheimers disease



**APP**  
amyloid beta precursor protein  
Synonyms: A4, AD1

Functions as a cell surface receptor, involved in neurite growth, neuronal differentiation, and cell cycle regulation.



We will land on a page like this:

**Open Targets Platform** Survey About ▾ Help ▾ API ▾ Downloads Blog 1

## APP


amyloid beta precursor protein | View associated diseases

Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, cell motility and transcription regulation through protein-protein interactions. Can promote transcription activation through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) and G(i) signaling. Membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis. Metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain ... [\[show more\]](#)

Synonyms: A4 AD1 CVAP Amyloid beta A4 protein PN-II peptidase nexin-II Cerebral vascular amyloid peptide Beta-amyloid protein  
APPI PreA4 Alzheimer disease amyloid protein APP

- Protein Information (from UniProt)
- Variants, isoforms and genomic context
- Protein baseline expression
- RNA baseline expression
- Gene Ontology
- Protein Structure
- Pathways

To find what which amino acids of this membrane receptor correspond to the extracellular domain, we need to expand the tab 'Protein Information (from UniProt)', click on 'Graphical', then expand the 'Topology' section in the image:



Click on the red boxes in 'Topology' to get a pop up window with more information. You will find out the extracellular domain is between amino acid 18 and 699.

---

---

## **HANDS-ON EXERCISES**

---

### **Exercise 1**

**Let's go back to Hutchinson-Gilford progeria, the example of the rare disease mentioned during the talk**

#### **BACKGROUND**

Hutchinson-Gilford progeria syndrome is a rare, fatal, autosomal dominant and premature aging disease. You have done a literature search using PubMed, perhaps even did a google search to find out more about this syndrome.

#### **QUESTIONS**

a) Can you compare the results from PubMed and Google to what you get from the Open Targets Platform? Look for the gene (s) linked to the disease based on the literature or genetic information (mutations for example). Can you find information on mouse models for example?

Pay attention on how quick you can get that information across the different platforms.

b) Lets focus on the Open Targets Platform with data integrated (analysed, ranked, scored) for this disease.

What are the top five targets associated with Hutchinson-Gilford progeria when taking into account all evidence integrated in the Platform?

b) Filter the result based on Genetic association only. How many genes are left? Can you list the mutations that support the association between this target and Hutchinson-Gilford progeria? Have a look at the Browser view to see whether these variants fall in the 5'UTR or 3'UTR, for example.

c) How many mouse models seem to mimic some of the phenotype of the disease?

## EXTRA HANDS-ON EXERCISES

### Exercise 2

#### **The *EGFR* gene, a receptor tyrosine kinase**

##### BACKGROUND

*EGFR* is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine auto-phosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer.

##### QUESTIONS

- a) How long is the protein encoded by this gene/target?
- b) Which tissue has the highest RNA baseline expression from the GTEx project
- c) Can you name the drug currently in clinical trial IV, status terminated, targeting this gene in non-small cell lung carcinoma?
- d) OSIMERTINIB is another drug targeting *EGFR* also in clinical trials phase IV for many carcinomas. Does this drug target other kinases than EGFR? (Tip: you will be searching for this drug in the Open Targets Platform).

---

### Exercise 3

***Using the Open Targets Platform to find out if the modulation of a target by a drug poses any possible unsafe interactions or effects.***

##### BACKGROUND

*The main goals of drug development are effectiveness and safety. Although no drug is 100% safe (they all have side effects), the benefits of the drugs should outweigh the known risks.*

##### SIGNIFICANCE

*Many drugs used on the treatments of diseases can interfere with other physiological processes and even cause death when taken in excess. One of the ways to start assessing the safety of a new compound is to look at which target it modulates, whether or not this target is involved in other therapeutic areas such as cardiovascular and reproductive system, and the expression of the gene (or protein) in normal tissues.*

#### *USE CASE*

*Abemaciclib has been shown in vitro to be a selective ATP-competitive inhibitor of CDK6 kinase activity. CDK6 has been shown to phosphorylate and thus regulate the activity of tumor suppressor protein Rb. Expression of this gene is increased in some types of cancer.*

*Abemaciclib is under investigation in patients with breast carcinoma among other types of cancer.*

#### *QUESTIONS*

*a) Are there studies showing a decreased level of RNA expression of this gene in breast carcinoma?*

*b) Is this target associated with cardiovascular diseases with a strong confidence (i.e. score of 0.80 or above)?*

---

## **QUICK GUIDE TO DATABASES**

Here is a list of databases and projects that may be useful for you to explore:

### **PROTEINS**

**UniProtKB** – The “Protein knowledgebase” is a comprehensive set of protein sequences. It is divided into two parts: TrEMBL and Swiss-Prot. The later is manually annotated and reviewed, therefore provides a set of protein sequences of high quality.

<http://www.uniprot.org/>

### **GENE NOMENCLATURE COMMITTEES**

**HGNC** – The HUGO Gene Nomenclature Committee assigns unique names and symbols to every single human gene, whether they are coding or not. These gene names and symbols are the official ones for human genes.

<http://www.genenames.org/>

**MGI** – The HGNC counterpart for naming mouse genes and symbols.

<http://www.informatics.jax.org/>

### **GENETIC VARIANTS and SOMATIC MUTATIONS**

**GWAS catalog**– The catalog of Genome Wide Association Studies (GWAS) provides genetic variants (e.g. SNPs) that are associated with a disease.

<https://www.ebi.ac.uk/gwas/>

**EVA** – The European Variation Archive (EVA) provides genetic variants and somatic mutations (associated with cancer).

<https://www.ebi.ac.uk/eva/>

**Cancer Gene Census** – A catalogue of genes for which mutations have been causally implicated in cancer. The Catalogue of Somatic Mutations in Cancer (COSMIC) at the Wellcome Trust Sanger Institute provides us with the set of genes associated with specific cancers in



the Cancer Gene Census, in addition to other cancers associated with that gene in the COSMIC database.

[www.cancer.sanger.ac.uk/census/](http://www.cancer.sanger.ac.uk/census/)

**IntOGen** - It provides evidence of somatic mutations, genes and pathways involved in tumorigenesis from 6,792 samples across 28 cancer types.

<https://www.intogen.org/search>

**Gene2Phenotype** - The data in Gene2Phenotype (G2P) provides evidence of genetic variants that are manually curated from the literature by consultant clinical geneticists in the UK. This is provided by DECIPHER, a database of genomic variants and phenotypes in patients with developmental disorders.

<https://www.ebi.ac.uk/gene2phenotype>

## **DRUGS**

**ChEMBL** - The ChEMBL database at the EMBL-EBI provides evidence from known drugs that can be linked to a disease and a known target.

<https://www.ebi.ac.uk/chembl/>

## **RNA EXPRESSION**

**Expression Atlas** - The Expression Atlas at EMBL-EBI provides information on genes that are differentially expressed between normal and disease samples, or among disease samples from different studies. In addition to differential expression, they provide baseline expression information for each gene.

<https://www.ebi.ac.uk/gxa/home>

## **AFFECTED PATHWAYS**

**Reactome** - The Reactome database at the EMBL-EBI contains pathway information on biochemical reactions sourced from manual curation. It identifies reaction pathways that are affected by pathogenic mutations.

<http://www.reactome.org/>

## **ANIMAL MODELS**

**Phenodigm** - The Phenodigm resource at the Wellcome Trust Sanger Institute provides evidence on associations of targets and disease. It uses a semantic approach to map between clinical features observed in humans and mouse phenotype annotations.

<http://www.sanger.ac.uk/resources/databases/phenodigm/>

## **TEXT MINING**

**Europe PMC** - The Europe PubMed Central at the EMBL-EBI mines the titles, abstracts and full text research articles from both PubMed and PubMed Central to provide evidence of links between targets and diseases.

<http://europepmc.org/>